Introduction
Over the past decade, the prevalence of women infected with HIV has increased in industrialized nations because of reduced mortality associated with the advent of combination antiretroviral therapy (ART) and higher rates of heterosexual HIV transmission [1] . A signi®cant proportion of these women will choose to conceive and carry pregnancies to term. Therapy of HIV infection during pregnancy must achieve the dual goals of maintaining maternal health and preventing viral transmission to healthy newborns.
Much progress has been made in recent years to identify the necessary components and timing of antiretroviral drug therapy to interrupt perinatal HIV transmission. How these principles should be incorporated into the plan of care for HIV-infected pregnant women is less clear. The Pediatric AIDS Clinical Trials Group Protocol 076 (PACTG 076) [2] demonstrated the bene®t of zidovudine prophylaxis in the prevention of HIV vertical transmission in 1994. Since then, placebo-controlled studies of other agents have largely been conducted in the developing world, where maternal treatment options are generally restricted to those available through study protocols. Extrapolation of these results to the care of HIV-infected pregnant women in industrialized nations must be carefully considered. Recently released guidelines on the use of antiretroviral drugs in pregnant women from the US Public Health Service Task Force [3 . . ] are formulated from recommendations that are based on established principles used to treat nonpregnant individuals.
We brie¯y review the principles of ART and discuss issues speci®c to potential risks and bene®ts to pregnant women and newborns. The review also focuses on the risk factors for vertical HIV transmission and on interventions, both drug-and nondrug-related [e.g. cesarean section (CS)] that may decrease that risk.
HIV replicates in most individuals at high rates from the time of acquisition. The virus, which must transcribe its genomic RNA into DNA in order to integrate into the host CD4 + lymphocyte, is prone to transcriptional errors. Some of these mutations are deleterious, whereas others may confer advantage to the progeny virus under certain selective conditions, such as the presence of antiretroviral drugs. Spontaneous development of mutations in wild-type HIV may produce virus with de-novo resistance to any one or two antiretroviral agents. Some individuals acquire infection with drug-resistant HIV, which may be overgrown by wild-type virus over time, but these persons may retain subpopulations of drugresistant virus that could rapidly re-emerge under selective drug pressure.
Effective ART must be potent enough to suppress the entire population of virus that has evolved in the infected individual. This will often require the use of at least three agents, usually from two or more drug classes. If less potent therapy that does not fully control viral replication is used, then further resistance will be selected for and breakthrough of viral suppression will occur. This outcome can result from either a poor choice of suppressive regimen, subtherapeutic drug levels (due to incomplete adherence, abnormal drug absorption/ metabolism, drug interaction that is unaccounted for), or a regimen designed for wild-type HIV that is inadequate for a drug-resistant strain transmitted at the time of seroconversion. Once viral resistance to a drug has evolved, mutated strains can remain`archived' in the long-lived pool of immune memory cells, only to be rapidly selected for if the drug is reintroduced. Therefore, in order to preserve future options for maternal treatment of HIV, choice of ART in HIV-infected pregnant women must be guided by the same principles that are used in nonpregnant patients.
Guidelines on acceptable antiretroviral combinations and how to manage treatment failures have recently been updated, and can be used to construct speci®c therapeutic options
]. Special considerations that are relevant to HIV and pregnancy are addressed below.
Timing of perinatal HIV transmission
Knowledge of the dynamics of vertical HIV transmission can be used to time interventions optimally in order to maximize their effectiveness. Although HIV can be transmitted from mother to child in utero, peripartum or postpartum via breastfeeding, the majority of transmission occurs peripartum [5] . Examination of tissue of aborted fetuses has demonstrated the presence of HIV and suggests the possibility of in utero transmission [6] . In that regard, the increased rate of spontaneous abortion in HIV-infected mothers compared with that in uninfected pregnant women provides further evidence for limited in utero transmission [5] .
A Thai study [7] tested heart blood from second trimester aborted fetuses for the presence of HIV-1 RNA, and found a transmission rate of only 5%. This suggests that the majority of vertical HIV transmission occurs during later stages of pregnancy. ART, especially if used during the third trimester or during labor, would not be effective at reducing early in utero transmission. Fortunately, most incidences of transmission (up to 80%) are estimated to occur peripartum [5, 8] ] followed 552 HIV-infected pregnant women, of whom 321 used no ART. They reported that perinatal transmission rates were 0% when HIV-1 RNA was less than 1000 copies/ml, and increased stepwise as maternal VL increased: 20.0% with HIV-1 VL 1000± 10 000 copies/ml; 24.1% with HIV-1 VL 10 001±50 000 copies/ml; 31.6% with VL 50 001±100 000 copies/ml; and 63.3% with VL 4100 000 copies/ml. There was no VL above which transmission was always observed.
Although maternal VL seems paramount at predicting transmission, Sperling et al. [14] showed that perinatal transmission, albeit at an extremely low rate, did occur in mothers in the lowest VL quartile, and even if VL was below the quantitative limit of the assay used. Because no upper or lower threshold can be described, VL data, although useful in assessing risk, cannot de®nitively predict whether transmission will or will not occur.
Low maternal CD4 + cell counts at the time of delivery have been associated with increased risk of transmission [11
. . ]. However, this association was established before the availability of VL measurements. A low CD4 + cell count may be a surrogate marker of high maternal viral burden.
Delivery related factors
Prolonged rupture (54 h) of fetal membranes, which increases newborn exposure to maternal blood/bodȳ uids, has been shown to increase the risk of vertical transmission [15] . Other delivery related factors, such as placental abruption, use of fetal scalp electrodes, performing an episiotomy, labor-induced vaginal lacerations, chorioamnionitis, and presence of ulcerative sexually transmitted diseases in the maternal genital tract may similarly expose the newborn to maternal blood or secretions [16±18] . Procedures such as amniocentesis and chorionic villus sampling, which are usually performed during the ®rst or second trimester, may also risk intrapartum transmission [11 . . , 17, 18] . Although these obstetric factors/complications are important, they only contribute to the mode by which HIV is most often transmitted, namely labor and a spontaneous vaginal delivery.
High levels of HIV in cervicovaginal¯uid have been shown [19 . ] to increase the risk of vertical HIV transmission. Chuachoowong et al. [19 . ] found that short-course antepartum zidovudine administration decreased cervicovaginal HIV RNA levels and reduced the rate of perinatal transmission. 
] of 15
prospective cohort studies examined mode of delivery and the risk of vertical HIV transmission in approximately 8000 HIV-infected pregnant women. The results showed a signi®cantly lower risk of vertical transmission after an elective CS compared with either a vaginal delivery or CS performed after membranes had ruptured. Even though ART reduced transmission rates to 7.3% in HIV-infected mothers who did not undergo elective CS, mothers who had an elective CS and took ART had a rate of transmission of only 2%. These results are impressive, but were accumulated prior to the use of highly active antiretroviral therapy (HAART) during pregnancy.
The bene®t of elective CS may be lost if maternal VLs are substantially suppressed at the time of delivery. HIVinfected pregnant women have higher rates of postoperative complications and infections, particularly when such procedures are performed in resource-poor nations [21] . The usefulness of elective CS in countries where potent ART options are available may be reserved for those HIV-infected pregnant women who have uncontrolled VLs at the time of delivery.
Breastfeeding
The major postpartum risk of HIV transmission is breastfeeding. A recent Kenyan study [22 . . ], in ARTnaõ Ève pregnant women, compared infant HIV-1 infection and mortality rates during the ®rst 24 months of life in HIV-infected pregnant women who breastfed (n = 197) and those who used formula feeds (n = 204). Sixty-one infants became HIV seropostive in the breastfeeding arm compared with 31 who were given formula. Not only were the cumulative HIV infection rates statistically much higher in the breastfeeding arm, but, interestingly, more than half of the overall risk difference was observed by 6 weeks of life, with additional continuous risk over the remaining 22 months of the study. The results from this and other studies [23, 24] provide compelling evidence for the risk of HIV transmission with breastfeeding.
In industrialized countries this important risk factor has been effectively curtailed by advising all HIV-infected mothers not to breastfeed their offspring. Such an injunction is more dif®cult to implement in resourcepoor countries, where ready, affordable provision of formula coupled with access to a clean water supply remains problematic outside the purview of clinical trials.
Factors that affect susceptibility to HIV infection
It has been observed [25] that certain individuals have had signi®cant or repeated exposure to HIV without becoming infected. Recent studies [26] have shown that, in order for HIV to infect a host lymphocyte, glycopeptides on the surface of HIV (gp160) must interact with both CD4 and a coreceptor. The coreceptors are chemokine receptors of two types: CCR5, which is preferentially bound by macrophage tropic (M-tropic) HIV; and CXCR4, which is preferentially bound by Tcell tropic HIV. M-tropic virus is predominantly selected when sexual, parenteral, and vertical transmission occurs. A 32-base-pair deletion in the CCR5 gene (D32) will generate a severely truncated form of CCR5 that will not function as a coreceptor for HIV [27] . Individuals who are homozygous for the D32 mutation are highly resistant to infection with M-tropic virus [25] . A study of 552 perinatally HIV exposed infants from New York and California [28 . ] was conducted to determine the effect of this mutation on vertical HIV transmission. Homozygousity for the D32 mutation was observed in 1% of uninfected babies, but in none of 151 HIV-infected babies (P50.001). There was no protective effect from being heterozygous for the D32 mutation. Unfortunately, the frequency of the D32 allele is low in the populations in the USA in which vertical HIV transmission is highest (blacks and Latinos).
Polymorphisms in the regulatory regions of the CCR5 gene may lead to varying levels of its expression on T lymphocytes, which can render a cell more or less susceptible to infection with HIV [29] . One polymorphism (CCR5-59356-T), which is more common among African-Americans than among Caucasians or Hispanics, has been associated with a nearly sixfold increased risk of vertical HIV transmission in infants who are homozygous for the allele [29] . Further study of this allele and how other chemokine receptor mutations may affect HIV transmission rates is required. Table 2 outlines the major clinical trials that have supported the use of ART in reducing vertical HIV transmission. In the USA, the initial use of zidovudine monotherapy has been largely replaced by combination ART following recommendations formulated by the US Public Health Service Task Force in 1998 [40] . PACTG 076 [2] demonstrated that administration of zidovudine in three stages (antepartum, intrapartum, and postpartum to the neonate) reduced perinatal HIV transmsission from 25% to 8.5%. PACTG 185 [41] demonstrated that the addition of HIV-speci®c immune globulin (given antepartum and single dose to the neonate) to zidovudine offered no bene®t over zidovudine alone in reducing HIV transmission.
Antiretroviral therapy to prevent perinatal HIV transmission
Because of the expense and complexity of the complete PACTG 076 regimen, which may be prohibitive in resource-poor areas, studies were conducted in Thailand, Cote d'Ivoire and Burkina Faso [30±32] in order to determine whether shorter courses of zidovudine were as effective. Much of the effect of the 076 regimen was preserved (37±50%, depending on the practice of breastfeeding) when zidovudine was used only during the last 2±4 weeks of pregnancy and intrapartum with or without a week of zidovudine for the neonate. Wade et al.
[42 . . ] demonstrated that zidovudine continued to show signi®cant bene®t even if therapy was ®rst initiated within a few hours after birth. These studies lend support to the notion that, because most transmission of HIV occurs near the time of delivery, zidovudine in these cases may be functioning as postexposure prophylaxis to the neonate. In this capacity, the effect of zidovudine is not to decrease maternal VL, but rather is to block transmission of virus after the neonate is exposed to contaminated maternal¯uids. Indeed, a number of studies [13 . . ,14] have shown that zidovudine monotherapy has little effect on maternal HIV-1 plasma VL. Therefore, zidovudine may function in much the same way as it does when used to prevent HIV transmission after needle stick exposure in a health care worker [43] . HIV transmitted peripartum often represents a single quasispecies and, because of the highly selective nature of the transmission, may be less diverse than the overall viral population that has evolved in the mother [44 . ].
Transmission of resistant (including multidrug resistant) HIV from mother to child has been documented [45,46 . ]. Frenkel et al. [45] reported up to 25% of HIV strains obtained from women treated with zidovudine monotherapy had resistance mutations to zidovudine, including an isolate transmitted to an infected neonate. Therefore, as in other settings in which ART is used for postexposure prophylaxis, it is prudent to use therapy that will effectively block a population of virus that may contain resistant strains.
Maternal plasma HIV-1 VL is a strong predictor of risk of perinatal HIV transmission, as reviewed above. Because zidovudine monotherapy appears to have little effect on VL and may lead to the selection of resistant virus in the mother, studies such as PETRA [34] were designed to determine whether combination therapy may give additional bene®t to that conferred by zidovudine alone by working to decrease maternal viral load, while retaining the bene®t of postexposure prophylaxis. PETRA demonstrated signi®cant reductions in perinatal HIV transmission with use of zidovudine and lamivudine. However, data on its effect on maternal VL have not been presented. Because only one mutation (M184V) in the HIV-1 reverse transcriptase gene is required to cause high-level lamivudine resistance, the combination of zidovudine with lamivudine may not maintain viral suppression in some individuals. Rapid evolution of lamivudine resistance in up to 80% of viral strains has been described with the use of zidovudine and lamivudine combinations during pregnancy [46 . ]. More complete and durable viral suppression may be possible with the use of HAART, which is composed of nucleoside analog reverse transcriptase inhibitors (NRTIs; such as zidovudine and lamivudine), together with a non-nucleoside analog reverse transcriptase inhibitor (NNRTI; such as nevirapine), and/or a protease inhibitor (such as nel®navir). A number of retrospective, noncontrolled studies of HAART therapy [35 . . ,36,37 . ,38 . ,39
. . ], involving over 500 mother±infant pairs, have reported reduction in perinatal HIV transmission rates to below 2% (Table 2) . Controlled, prospective trials of proteasecontaining combination therapies for prevention of vertical HIV transmission are currently underway.
A study that generated a tremendous amount of interest during the past year was HIVNET 012 [33
. . ], conducted in Uganda, in which nevirapine was found to reduce perinatal HIV transmission 47% more effectively than zidovudine when initiated at the onset of labor and for the equivalent of 1 week postpartum in the neonate. HIVNET 006 [47] , a preliminary study of the pharmacokinetics of nevirapine during pregnancy, demonstrated that plasma levels of nevirapine were maintained above the level needed to inhibit viral strains for over 1 week after a single 200 mg oral dose, and that 61% of plasma levels were present in breast milk. The favorable pharmacokinetics of nevirapine may have been bene®cial in HIVNET 012, since the entire regimen consisted of a single 200 mg tablet that the mother was instructed to take at the onset of labor, and a second dose of nevirapine suspension given by the study nurse to the newborn at 72 h after birth. (An additional dose was given immediately after birth only to those neonates whose mother did not receive the intrapartum dose, or who were delivered within 1 h of the intrapartum dose.) Zidovudine on the other hand was given every 3 h in labor, and had to be administered twice a day by the mother to the newborn for 1 week. Differing adherence with the regimens, rather than potency, may have affected outcome. In addition, zidovudine must undergo intracellular phosphorylation in order to be active against HIV, whereas nevirapine requires no processing to be active. This difference may represent a signi®cant bene®t with nevirapine treatment, because therapy was initiated after labor had already started, and the time needed for phosphorylation of zidovudine may have signi®cantly impacted on outcome.
Similar to lamivudine, HIV resistance to nevirapine requires only a single mutation in the reverse transcriptase gene. Due to the long half-life of elimination (over 60 h) of NVP after a single dose, HIV resistance mutations were selected in three out of 14 women after peripartum administration [48 . . ]. One of the mutations selected by nevirapine (K103N) has been assosciated with cross-resistance to all currently available NNRTI agents. The long-term effect on subsequent response to ART of the selection of virus with NNRTI-resistance mutations is unclear. The use of nevirapine as part of combination therapy initiated earlier in the antepartum period may be less problematic. Nevirapine induces its own metabolism via the cytochrome P450 enzyme pathway in the liver; this induction takes about 2 weeks to occur. Once induction of hepatic metabolism has taken place, the half-life of nevirapine will be shorter; also, the washout period, during which time subtherapeutic drug levels occur that are more likely to select for drug-resistant viral strains, will also be shorter. Therefore, with chronic use as part of a fully suppressive ART combination, resistance to nevirapine is less likely to emerge. However, because nevirapine crosses the placenta, chronic antenatal use of the drug will also induce hepatic metabolism in the fetus. Therefore, sustained blood levels in the newborn will not be maintained after a single postpartum dose, and more regular dosing of nevirapine may be required for prophylaxis.
Because perinatal HIV transmission from mothers on antepartum HAART may be very rare, the addition of nevirapine in labor may not provide them with further demonstrable bene®t. As with elective CS, the role of intrapartum nevirapine must be re®ned. Clarke et al.
[39
. . ] added nevirapine to the regimen of 11 women who had detectable plasma VL despite use of combination ART at 38 weeks gestation. Six of the women achieved undetectable VLs at the time of delivery, and none of the 11 women transmitted HIV to their babies. Use of intrapartum nevirapine in such selected cases or in combination with zidovudine or other agents for women who present for ®rst care at the time of labor may be appropriate. Unless other agents are not available, however, use of nevirapine monotherapy should be avoided until data on long-term resistance are more complete.
Use of antiretroviral therapy during pregnancy
Although much attention has been focused on the use of ART during pregnancy to prevent perinatal HIV transmission, it is important to choose therapy that will be appropriate to maintain and improve the health status of the mother and avoid long-term effects that may compromise future therapy, such as the development of drug-resistant viral strains. Incorporation of information gleaned from clinical trials on HIV transmission into therapeutic decisions for the mother's antiretroviral combination is an important part of managing HIV in pregnancy.
Many pregnant women with HIV may be in early stages of their infection and may not meet criteria for initiation of ART, but are started only to prevent perinatal transmission. Use of zidovudine monotherapy in such cases may lead to evolution of resistant virus that may affect response to subsequent therapy. Recently released guidelines from the US Public Health Task Force [3
. . ] recommend that ART is chosen utilizing the same considerations as are used for nonpregnant women. HIVinfected women, who are already on ART, who become pregnant should be counseled with regard to the risks and bene®ts of continuing their regimen during the ®rst trimester. If therapy is interrupted, all agents must be stopped and then restarted simultaneously. Women who are not on ART at the time pregnancy is diagnosed should consider initiating ART after 14 weeks of gestation. It is important to discuss potential risks and bene®ts of using ART during pregnancy. 
Safety of antiretroviral therapy during pregnancy
The long-term safety of exposure of the fetus to antiretroviral agents has not been established. Animal and human studies [3 . . ] have demonstrated that all the NRTIs cross the placenta. ] has identi®ed 227 deaths from over 20 000 HIV-exposed, uninfected children. None of the children died of illnesses compatable with mitochondrial toxicity. Further investigation for potential cases with milder presentations is warranted. The French report [52] does not require a change in guidelines, but long-term follow-up of all ART-exposed children for signs of mitochondrial toxicity with uniform reporting must be a routine part of their care.
Use of HIV-1 resistance testing assays during pregnancy
Recently published guidelines from the International AIDS Society±USA [54
. . ], recommend the use of HIV-1 resistance testing during pregnancy. HIV resistance testing can be useful to identify the presence of preexisting resistant viral strains that may have been selected from prior antiretroviral exposure or from primary acquisition of a resistant strain. Caution must be exercised in interpreting assay results, because in the absence of ongoing selective pressure (i.e. after the patient has discontinued the failing drug) resistant viral strains will decrease in proportion to the more ®t wildtype strains and may be missed by the assay. Therefore, the resistance assay can be useful in identifying drugs to which the virus is probably resistant, but it cannot safely predict drugs to which the virus is susceptible. If a mother has detectable VL while on antepartum combination ART, results of resistance testing can help in planning or modifying prophylactic therapy for the newborn, as well as in selecting the next potent combination for the mother. HIV resistance testing can also help distinguish failure of response to therapy due to drug resistance from lack of adherence. A more acceptable combination may be substituted, or resources can be directed toward overcoming adherence barriers, rather than changing to more complex salvage therapy that may not be indicated.
Adherence to and pharmacokinetics of antiretroviral therapy in pregnancy
It is important that, in addition to being potent, therapy must also be convenient in order to promote adherence. Recent work [55] has suggested that in an ART-naõ Ève patient, as long as a potent combination is chosen, adherence to therapy is the most important determinant of virologic response. During pregnancy, many factors may affect the tolerability of ART. If possible, the regimen should be tailored to be given no more than twice a day, and without food and¯uid restrictions. If patients complain of side effects such as nausea, they should be promptly addressed to avoid nonadherence. Pharmacokinetics of antiretroviral agents during pregnancy and drug interactions, especially with methadone and anesthetic agents that may be used during labor, must be further studied. An analysis of PACTG 076 data [56
. . ] recently reported that pregnant women in the highest weight quartile (482 kg) had only a 26% reduction in HIV transmission with use of zidovudine compared with 79% for those in the other quartiles. Effects of pregnancy and obesity may alter the volume of distribution of zidovudine, leading to decreased plasma and intracellular concentrations with lower transplacental passage to the fetus [56
. . ].
Conclusion
Managing HIV therapy in pregnancy has undergone many changes over the past few years. The results of ongoing studies will hopefully clarify the role of combination therapy in pregnancy, and provide more information on safety. At this time elective CS cannot be recommended for all HIV-infected pregnant women. Prospective studies are needed to de®ne the role of elective CS in women with suppressed viremia at the time of delivery. However, such studies will require a large cohort in order to demonstrate the added bene®t of elective CS, because perinatal HIV transmission rates with the use of effective combination ART are extremely low.
Although the present review focuses much attention on the role of HAART in pregnancy, the availability of ART for the majority of the world's pregnant women infected with HIV is woefully lacking. Imaginative and thoughtful leadership by health planners and governments is urgently required to shift resources in favor of the millions of people infected with this devastating virus.
